Jiao-Yu Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiao-Yu Deng has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
Jing Gu
Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology (CAS), Wuhan, China
20 shared publications- Xian-En Zhang
Institute of Biophysics, Chinese Academy of Sciences
12 shared publications Kun Li
Department of Medical Laboratory, Guangzhou Chest Hospital, Guangzhou Medical University, Guangdong, China
6 shared publicationsXude Wang
Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
5 shared publicationsJifang Yu
Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology (CAS), Wuhan, China
4 shared publicationsShanshan Yang
Wuhan Institute of Virology, Chinese Academy of Sciences
4 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-9
Mutations in oxyR and oxyR-ahpC Interogenic Region in Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates from Chongqing, China
Background and Aim: As a first line anti-tuberculosis drug, isoniazid (INH) has been extensively used for decades. Consequently, resistance of Mycobacterium tuberculosis (MTB) clinical isolates to INH is inevitably increasing and spreading, necessitating fast and accurate molecular diagnosis tools. Although many previous molecular epidemiological studies related with INH resistance included mutations in the oxyR-ahpC intergenic region, the role of mutations in the oxyR-ahpC intergenic region in INH resistance remains controversial. The present study aimed to investigate the frequency and distribution of mutations in the ahpC and the oxyR-ahpC intergenic region among INH-resistant Mycobacterium tuberculosis (MTB) clinical isolates in Chongqing, China. Methods: The presence of mutations in katG, ahpC and the oxyR-ahpC intergenic region was analyzed in 490 MTB clinical isolates. Results: None of the 73 INH-susceptible isolates (0%), 18 of 26 INH mono-resistant isolates (69.2%), 188 of 199 MDR (multidrug resistant) isolates (94.5%), and 176 of 192 pre-XDR/XDR (pre-extensively drug-resistant) isolates (91.7%) had mutations in katG. No mutations in ahpC, oxyR and the oxyR-ahpC intergenic region were identified in INH-susceptible and INH mono-resistant isolates. Mutations in the oxyR-ahpC intergenic region were rare (1.5% MDR, 1.04% pre-XDR), and only two mutations were identified (− 58 G→A in MDR and − 54 C→T in pre-XDR isolates). The former occurred in isolates with concurrent katG mutations, but the latter occurred in isolates without concurrent katG mutations. Notably, a novel Ala18Gly mutation in oxyR was identified in 3.52% of MDR and 6.77% of pre-XDR isolates. Conclusion: Mutation in katG is the main cause of INH resistance in MTB clinical strains isolated from Chongqing. It is very unlikely that mutation in the oxyR-ahpC intergenic region alone could cause INH resistance in MTB clinical isolates. Even though mutation in the oxyR-ahpC intergenic region could compensate the fitness cost of katG mutation, our finding that it is uncommon in MTB clinical isolates from Chongqing suggests it is not the primary compensatory mechanism. Further investigation is necessary to probe the relationship between mutations in the coding region of oxyR and INH resistance.
- 1 January 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-9
Open AccessMutations in oxyR and oxyR-ahpC Interogenic Region in Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates from Chongqing, China
Background and Aim: As a first line anti-tuberculosis drug, isoniazid (INH) has been extensively used for decades. Consequently, resistance of Mycobacterium tuberculosis (MTB) clinical isolates to INH is inevitably increasing and spreading, necessitating fast and accurate molecular diagnosis tools. Although many previous molecular epidemiological studies related with INH resistance included mutations in the oxyR-ahpC intergenic region, the role of mutations in the oxyR-ahpC intergenic region in INH resistance remains controversial. The present study aimed to investigate the frequency and distribution of mutations in the ahpC and the oxyR-ahpC intergenic region among INH-resistant Mycobacterium tuberculosis (MTB) clinical isolates in Chongqing, China. Methods: The presence of mutations in katG, ahpC and the oxyR-ahpC intergenic region was analyzed in 490 MTB clinical isolates. Results: None of the 73 INH-susceptible isolates (0%), 18 of 26 INH mono-resistant isolates (69.2%), 188 of 199 MDR (multidrug resistant) isolates (94.5%), and 176 of 192 pre-XDR/XDR (pre-extensively drug-resistant) isolates (91.7%) had mutations in katG. No mutations in ahpC, oxyR and the oxyR-ahpC intergenic region were identified in INH-susceptible and INH mono-resistant isolates. Mutations in the oxyR-ahpC intergenic region were rare (1.5% MDR, 1.04% pre-XDR), and only two mutations were identified (− 58 G→A in MDR and − 54 C→T in pre-XDR isolates). The former occurred in isolates with concurrent katG mutations, but the latter occurred in isolates without concurrent katG mutations. Notably, a novel Ala18Gly mutation in oxyR was identified in 3.52% of MDR and 6.77% of pre-XDR isolates. Conclusion: Mutation in katG is the main cause of INH resistance in MTB clinical strains isolated from Chongqing. It is very unlikely that mutation in the oxyR-ahpC intergenic region alone could cause INH resistance in MTB clinical isolates. Even though mutation in the oxyR-ahpC intergenic region could compensate the fitness cost of katG mutation, our finding that it is uncommon in MTB clinical isolates from Chongqing suggests it is not the primary compensatory mechanism. Further investigation is necessary to probe the relationship between mutations in the coding region of oxyR and INH resistance.
- Open Access
- 23 September 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (9) , e0047825
An African swine fever virus-specific antibody reactome reveals antigens as potential candidates for vaccine development
Developing an efficient and safe vaccine for African swine fever (ASF), a devastating disease of pigs, remains a significant challenge mainly due to limited knowledge of the immune correlates of protection. Identifying protective determinants is difficult because ASF virus (ASFV) is a large and complex DNA virus encoding over 160 proteins. Here, we constructed an ASFV proteome microarray containing 160 full-length proteins for profiling ASFV-specific antibodies. An antibody reactome containing 46 ASFV proteins (including 12 newly recognized B-cell antigens) was established by analyzing several cohorts of serum samples from pigs protected with different live-attenuated vaccines (LAVs). A proteome-wide study of antibody dynamics over a 26-day period provided a multi-dimensional landscape of the host humoral response against ASFV after acute infection, LAV immunization, and post-vaccination challenge. This study provides a comprehensive understanding of ASFV-induced humoral immune responses, highlights B-cell antigen candidates for vaccine design, supports the investigation of LAV protection mechanisms, and would accelerate vaccine development. IMPORTANCE: African swine fever (ASF) poses a severe threat to global swine industries, with vaccine development hindered by limited understanding of immune protection. A comprehensive understanding of antibody responses against ASF virus (ASFV) and the discovery of protective antigens are fundamental to vaccine development. This study constructed an ASFV proteome microarray to profile antibody responses against 160 viral proteins and established the antibody spectra against ASFV with dynamic features. The proteome microarray offers a high-throughput platform for understanding ASFV immunology and pathogenicity and will contribute to ASF vaccine development and diagnosis.
- 23 September 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (9) , e0047825
Open AccessAn African swine fever virus-specific antibody reactome reveals antigens as potential candidates for vaccine development
Developing an efficient and safe vaccine for African swine fever (ASF), a devastating disease of pigs, remains a significant challenge mainly due to limited knowledge of the immune correlates of protection. Identifying protective determinants is difficult because ASF virus (ASFV) is a large and complex DNA virus encoding over 160 proteins. Here, we constructed an ASFV proteome microarray containing 160 full-length proteins for profiling ASFV-specific antibodies. An antibody reactome containing 46 ASFV proteins (including 12 newly recognized B-cell antigens) was established by analyzing several cohorts of serum samples from pigs protected with different live-attenuated vaccines (LAVs). A proteome-wide study of antibody dynamics over a 26-day period provided a multi-dimensional landscape of the host humoral response against ASFV after acute infection, LAV immunization, and post-vaccination challenge. This study provides a comprehensive understanding of ASFV-induced humoral immune responses, highlights B-cell antigen candidates for vaccine design, supports the investigation of LAV protection mechanisms, and would accelerate vaccine development. IMPORTANCE: African swine fever (ASF) poses a severe threat to global swine industries, with vaccine development hindered by limited understanding of immune protection. A comprehensive understanding of antibody responses against ASF virus (ASFV) and the discovery of protective antigens are fundamental to vaccine development. This study constructed an ASFV proteome microarray to profile antibody responses against 160 viral proteins and established the antibody spectra against ASFV with dynamic features. The proteome microarray offers a high-throughput platform for understanding ASFV immunology and pathogenicity and will contribute to ASF vaccine development and diagnosis.
- Open Access
- 26 August 2025
- Published by Elsevier in Microbiological Research
- Vol. 301, 128323
Combined use of vitamin C and antifolates induces cuproptosis-like bacterial death
- 26 August 2025
- Published by Elsevier in Microbiological Research
- Vol. 301, 128323
Open AccessCombined use of vitamin C and antifolates induces cuproptosis-like bacterial death
- Open Access
- 18 August 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 497, 139582
Stepwise degradation of bisphenol A into various monocyclic aromatic hydrocarbons by a P450 enzyme BisdB in Sphingobium yanoikuyae GDP
- 18 August 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 497, 139582
Open AccessStepwise degradation of bisphenol A into various monocyclic aromatic hydrocarbons by a P450 enzyme BisdB in Sphingobium yanoikuyae GDP
- Open Access
- 30 May 2025
- Published by Elsevier in EBioMedicine
- Vol. 117, 105776
Diverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin
- 30 May 2025
- Published by Elsevier in EBioMedicine
- Vol. 117, 105776
Open AccessDiverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin
- 27 July 2024
- Published by Elsevier in Tuberculosis
- Vol. 148, 102551
The rv2820c K114N mutation is related with capreomycin tolerance
- 27 July 2024
- Published by Elsevier in Tuberculosis
- Vol. 148, 102551
The rv2820c K114N mutation is related with capreomycin tolerance
- Open Access
- 24 July 2024
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 13 (1) , 2374030
The T120P or M172V mutation on rv2172c confers high level para -aminosalicylic acid resistance in Mycobacterium tuberculosis
Although para-aminosalicylic acid (PAS) has been used to treat tuberculosis for decades, mechanisms of resistance to this drug in Mycobacterium tuberculosis (M. tuberculosis) clinical isolates have not been thoroughly investigated. Previously, we found that decreased methylenetetrahydrofolate reductase (MTHFR) activity of Rv2172c led to increased sensitivity to antifolates in M. tuberculosis. In this study, we collected the genome-sequencing data of 173 PAS-resistant and 803 PAS-sensitive clinical isolates and analyzed rv2172c mutations in those 976 isolates. The results showed that two mutations (T120P and M172V) on rv2172c could be identified in a certain proportion (6.36%) of PAS-resistant isolates. The results of AlphaFold2 prediction indicated that the T120P or M172V mutation might affect the enzymatic activity of Rv2172c by influencing nicotinamide adenine dinucleotide (NADH) binding, and this was verified by subsequent biochemical analysis, demonstrating the role of residues Thr120 and Met172 on NADH binding and enzymatic activity of Rv2172c. In addition, the effect of rv2172c T120P or M172V mutation on methionine production and PAS resistance was determined in M. tuberculosis. The results showed that both T120P and M172V mutations caused increased intracellular methionine concentrations and high level PAS resistance. In summary, we discovered new molecular markers and also a novel mechanism of PAS resistance in M. tuberculosis clinical isolates and broadened the understanding of the NADH-dependent MTHFR catalytic mechanism of Rv2172c in M. tuberculosis, which will facilitate the molecular diagnosis of PAS resistance and also the development of new drugs targeting Rv2172c.
- 24 July 2024
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 13 (1) , 2374030
Open AccessThe T120P or M172V mutation on rv2172c confers high level para -aminosalicylic acid resistance in Mycobacterium tuberculosis
Although para-aminosalicylic acid (PAS) has been used to treat tuberculosis for decades, mechanisms of resistance to this drug in Mycobacterium tuberculosis (M. tuberculosis) clinical isolates have not been thoroughly investigated. Previously, we found that decreased methylenetetrahydrofolate reductase (MTHFR) activity of Rv2172c led to increased sensitivity to antifolates in M. tuberculosis. In this study, we collected the genome-sequencing data of 173 PAS-resistant and 803 PAS-sensitive clinical isolates and analyzed rv2172c mutations in those 976 isolates. The results showed that two mutations (T120P and M172V) on rv2172c could be identified in a certain proportion (6.36%) of PAS-resistant isolates. The results of AlphaFold2 prediction indicated that the T120P or M172V mutation might affect the enzymatic activity of Rv2172c by influencing nicotinamide adenine dinucleotide (NADH) binding, and this was verified by subsequent biochemical analysis, demonstrating the role of residues Thr120 and Met172 on NADH binding and enzymatic activity of Rv2172c. In addition, the effect of rv2172c T120P or M172V mutation on methionine production and PAS resistance was determined in M. tuberculosis. The results showed that both T120P and M172V mutations caused increased intracellular methionine concentrations and high level PAS resistance. In summary, we discovered new molecular markers and also a novel mechanism of PAS resistance in M. tuberculosis clinical isolates and broadened the understanding of the NADH-dependent MTHFR catalytic mechanism of Rv2172c in M. tuberculosis, which will facilitate the molecular diagnosis of PAS resistance and also the development of new drugs targeting Rv2172c.
- Open Access
- 21 December 2023
- Published by MDPI AG in Antibiotics
- Vol. 13 (1) , 13
Competition between H4PteGlu and H2PtePAS Confers para-Aminosalicylic Acid Resistance in Mycobacterium tuberculosis
Tuberculosis remains a serious challenge to human health worldwide. para-Aminosalicylic acid (PAS) is an important anti-tuberculosis drug, which requires sequential activation by Mycobacterium tuberculosis (M. tuberculosis) dihydropteroate synthase and dihydrofolate synthase (DHFS, FolC). Previous studies showed that loss of function mutations of a thymidylate synthase coding gene thyA caused PAS resistance in M. tuberculosis, but the mechanism is unclear. Here we showed that deleting thyA in M. tuberculosis resulted in increased content of tetrahydrofolate (H4PteGlu) in bacterial cells as they rely on the other thymidylate synthase ThyX to synthesize thymidylate, which produces H4PteGlu during the process. Subsequently, data of in vitro enzymatic activity experiments showed that H4PteGlu hinders PAS activation by competing with hydroxy dihydropteroate (H2PtePAS) for FolC catalysis. Meanwhile, over-expressing folC in ΔthyA strain and a PAS resistant clinical isolate with known thyA mutation partially restored PAS sensitivity, which relieved the competition between H4PteGlu and H2PtePAS. Thus, loss of function mutations in thyA led to increased H4PteGlu content in bacterial cells, which competed with H2PtePAS for catalysis by FolC and hence hindered the activation of PAS, leading to decreased production of hydroxyl dihydrofolate (H2PtePAS-Glu) and finally caused PAS resistance. On the other hand, functional deficiency of thyA in M. tuberculosis pushes the bacterium switch to an unidentified dihydrofolate reductase for H4PteGlu biosynthesis, which might also contribute to the PAS resistance phenotype. Our study revealed how thyA mutations confer PAS resistance in M. tuberculosis and provided new insights into studies on the folate metabolism of the bacterium.
- 21 December 2023
- Published by MDPI AG in Antibiotics
- Vol. 13 (1) , 13
Open AccessCompetition between H4PteGlu and H2PtePAS Confers para-Aminosalicylic Acid Resistance in Mycobacterium tuberculosis
Tuberculosis remains a serious challenge to human health worldwide. para-Aminosalicylic acid (PAS) is an important anti-tuberculosis drug, which requires sequential activation by Mycobacterium tuberculosis (M. tuberculosis) dihydropteroate synthase and dihydrofolate synthase (DHFS, FolC). Previous studies showed that loss of function mutations of a thymidylate synthase coding gene thyA caused PAS resistance in M. tuberculosis, but the mechanism is unclear. Here we showed that deleting thyA in M. tuberculosis resulted in increased content of tetrahydrofolate (H4PteGlu) in bacterial cells as they rely on the other thymidylate synthase ThyX to synthesize thymidylate, which produces H4PteGlu during the process. Subsequently, data of in vitro enzymatic activity experiments showed that H4PteGlu hinders PAS activation by competing with hydroxy dihydropteroate (H2PtePAS) for FolC catalysis. Meanwhile, over-expressing folC in ΔthyA strain and a PAS resistant clinical isolate with known thyA mutation partially restored PAS sensitivity, which relieved the competition between H4PteGlu and H2PtePAS. Thus, loss of function mutations in thyA led to increased H4PteGlu content in bacterial cells, which competed with H2PtePAS for catalysis by FolC and hence hindered the activation of PAS, leading to decreased production of hydroxyl dihydrofolate (H2PtePAS-Glu) and finally caused PAS resistance. On the other hand, functional deficiency of thyA in M. tuberculosis pushes the bacterium switch to an unidentified dihydrofolate reductase for H4PteGlu biosynthesis, which might also contribute to the PAS resistance phenotype. Our study revealed how thyA mutations confer PAS resistance in M. tuberculosis and provided new insights into studies on the folate metabolism of the bacterium.
- Open Access
- 29 November 2023
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 12 (2) , 2276339
Association between mutations in a thyX-hsdS.1 region and para -aminosalicylic acid resistance in Mycobacterium tuberculosis clinical isolates
Although para-aminosalicylic acid (PAS) has been used to treat tuberculosis agent for decades, its mechanisms of resistance are still not thoroughly understood. Previously, sporadic studies showed that certain mutations in the thyX-hsdS.1 region caused PAS resistance in M. tuberculosis, but a comprehensive analysis is lacking. Recently, we found a G-10A mutation in thyX-hsdS.1 in a PAS-resistant clinical isolate, but it did not cause PAS resistance. SNPs in thyX-hsdS.1 in 6550 clinical isolates were analyzed, and 153 SNPs were identified. C-16 T was the most common SNP identified (54.25%, 83/153), followed by C-4T (7.19%, 11/153) and G-9A (6.54%, 10/153). Subsequently, the effects of those SNPs on the promoter activity of thyX were tested, and the results showed that mutations C-1T, G-3A, C-4T, C-4G, G-7A, G-9A, C-16T, G-18C, and C-19G led to increased promoter activity compared with the wild-type sequence, but other mutations did not. Then, thyX and wild-type thyX-hsdS.1, or thyX-hsdS.1 containing specific SNPs, were overexpressed in M. tuberculosis H37Ra. The results showed that mutations resulting in increased promoter activity also caused PAS resistance. Moreover, the results of an electrophoretic mobility shift assay showed that thyX-hsdS.1 containing the C-16T mutation had a higher binding capacity to RNA polymerase than did the wild-type sequence. Taken together, our data demonstrated that among the SNPs identified in thyX-hsdS.1 of M. tuberculosis clinical isolates, only those able to increase the promoter activity of thyX caused PAS resistance and therefore can be considered as molecular markers for PAS resistance.
- 29 November 2023
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 12 (2) , 2276339
Open AccessAssociation between mutations in a thyX-hsdS.1 region and para -aminosalicylic acid resistance in Mycobacterium tuberculosis clinical isolates
Although para-aminosalicylic acid (PAS) has been used to treat tuberculosis agent for decades, its mechanisms of resistance are still not thoroughly understood. Previously, sporadic studies showed that certain mutations in the thyX-hsdS.1 region caused PAS resistance in M. tuberculosis, but a comprehensive analysis is lacking. Recently, we found a G-10A mutation in thyX-hsdS.1 in a PAS-resistant clinical isolate, but it did not cause PAS resistance. SNPs in thyX-hsdS.1 in 6550 clinical isolates were analyzed, and 153 SNPs were identified. C-16 T was the most common SNP identified (54.25%, 83/153), followed by C-4T (7.19%, 11/153) and G-9A (6.54%, 10/153). Subsequently, the effects of those SNPs on the promoter activity of thyX were tested, and the results showed that mutations C-1T, G-3A, C-4T, C-4G, G-7A, G-9A, C-16T, G-18C, and C-19G led to increased promoter activity compared with the wild-type sequence, but other mutations did not. Then, thyX and wild-type thyX-hsdS.1, or thyX-hsdS.1 containing specific SNPs, were overexpressed in M. tuberculosis H37Ra. The results showed that mutations resulting in increased promoter activity also caused PAS resistance. Moreover, the results of an electrophoretic mobility shift assay showed that thyX-hsdS.1 containing the C-16T mutation had a higher binding capacity to RNA polymerase than did the wild-type sequence. Taken together, our data demonstrated that among the SNPs identified in thyX-hsdS.1 of M. tuberculosis clinical isolates, only those able to increase the promoter activity of thyX caused PAS resistance and therefore can be considered as molecular markers for PAS resistance.
- Open Access
- 21 December 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (6) , e0250122
CycA-Dependent Glycine Assimilation Is Connected to Novobiocin Susceptibility in Escherichia coli
Novobiocin (NOV) has been used in clinical practice as an ATPase inhibitor for decades. However, because it has been withdrawn from the market, pharmaceutical companies are searching for other ATPase inhibitors.
- 21 December 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (6) , e0250122
Open AccessCycA-Dependent Glycine Assimilation Is Connected to Novobiocin Susceptibility in Escherichia coli
Novobiocin (NOV) has been used in clinical practice as an ATPase inhibitor for decades. However, because it has been withdrawn from the market, pharmaceutical companies are searching for other ATPase inhibitors.